Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald S Falchook

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Cancer Chemotherapy and Pharmacology|November 13, 2012
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou, Mark B Leick, Joann Lim, et al.
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Investigational New Drugs|October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerGerald S Falchook, Stacy Moulder, Aung Naing, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Cancer Chemotherapy and Pharmacology|November 13, 2012
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou, Mark B Leick, Joann Lim, et al.
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Investigational New Drugs|October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerGerald S Falchook, Stacy Moulder, Aung Naing, et al.
Pageof 14